Afatinib in Patients With an EGFR Mutation
Giorgio V. Scagliotti, MD, PhD, from the University of Turin, San Luigi Hospital, Orbassano, Italy, discusses afatinib in patients with EGFR-mutated tumors.
Giorgio V. Scagliotti, MD, PhD, head of the Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Orbassano, Italy, discusses afatinib in patients with epidermal growth factor receptor (EGFR) mutated tumors.
Scagliotti does not claim that afatinib is better or worse than a reversible tyrosine kinase inhibitor (TKI). However, the LUX-Lung 3 and LUX-Lung 6 trials have shown that afatinib is better than chemotherapy for the treatment of patients with an EGFR mutation.
The high level of toxicity associated with afatinib will be tested in the LUX-Lung 7 trial, Scagliotti says, as afatinib will be compared to a reversible TKI.
Clinical Pearls
- Trials have shown that afatinib is better than chemotherapy when treating patients with EGFR mutation
- The trials also showed that afatinib has a higher level of toxicity.
- The LUX-Lung 7 trial will compare afatinib to a reversible tyrosine kinase inhibitor
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More
